CO6680653A2 - Fabricación del inhibidor inter-alfa(iaip) a partir de plasma - Google Patents

Fabricación del inhibidor inter-alfa(iaip) a partir de plasma

Info

Publication number
CO6680653A2
CO6680653A2 CO13035387A CO13035387A CO6680653A2 CO 6680653 A2 CO6680653 A2 CO 6680653A2 CO 13035387 A CO13035387 A CO 13035387A CO 13035387 A CO13035387 A CO 13035387A CO 6680653 A2 CO6680653 A2 CO 6680653A2
Authority
CO
Colombia
Prior art keywords
lalp
precipitate
fraction
plasma
manufacture
Prior art date
Application number
CO13035387A
Other languages
English (en)
Spanish (es)
Inventor
Shawn F Bairstow
Jennifer Hutsell
Sindhu Ramachandran
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of CO6680653A2 publication Critical patent/CO6680653A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/30Extraction; Separation; Purification by precipitation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CO13035387A 2010-07-23 2013-02-21 Fabricación del inhibidor inter-alfa(iaip) a partir de plasma CO6680653A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36733110P 2010-07-23 2010-07-23

Publications (1)

Publication Number Publication Date
CO6680653A2 true CO6680653A2 (es) 2013-05-31

Family

ID=44534634

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13035387A CO6680653A2 (es) 2010-07-23 2013-02-21 Fabricación del inhibidor inter-alfa(iaip) a partir de plasma

Country Status (14)

Country Link
US (2) US8841248B2 (enExample)
EP (1) EP2596014B1 (enExample)
JP (1) JP5830096B2 (enExample)
KR (1) KR20130093607A (enExample)
CN (1) CN103119058A (enExample)
AU (1) AU2011280907B2 (enExample)
BR (1) BR112013001753A2 (enExample)
CA (1) CA2806645A1 (enExample)
CO (1) CO6680653A2 (enExample)
EA (1) EA201390156A1 (enExample)
ES (1) ES2717177T3 (enExample)
MX (1) MX2013000958A (enExample)
SG (1) SG187599A1 (enExample)
WO (1) WO2012012773A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004289252C1 (en) 2003-11-08 2013-06-20 Prothera Biologics, Inc. Preparation and composition of Inter-alpha inhibitor proteins from human plasma for therapeutic use
AU2009260822B2 (en) 2008-05-28 2016-09-22 Prothera Biologics, Inc. Preparation and composition of Inter-alpha inhibitor proteins from blood
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8841248B2 (en) 2010-07-23 2014-09-23 Baxter International Inc. Manufacture of inter-alpha-inhibitor (IaIp) from plasma
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之i-iv-1部分沉澱
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) * 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
EP3512539A4 (en) 2016-09-13 2020-07-29 Prothera Biologics, Inc. METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS
BR112019022358A2 (pt) 2017-04-25 2020-05-19 Prothera Biologics Inc métodos para quantificar proteínas inibidoras inter-alfa
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
EP3870147A4 (en) * 2018-10-24 2022-08-31 Prothera Biologics, Inc. INTER-ALPHA INHIBITOR PROTEINS AND METHODS OF USE THEREOF
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法
EP3994165A1 (en) * 2019-07-04 2022-05-11 CSL Behring GmbH Process for purifying c1-inh
CA3173539A1 (en) * 2020-03-31 2021-10-07 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma
US20220380439A1 (en) * 2020-11-09 2022-12-01 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
AU2021377336A1 (en) 2020-11-16 2023-07-06 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins
JP2025514479A (ja) * 2022-05-02 2025-05-02 武田薬品工業株式会社 血漿から限外濾過によりコーンプール濃縮物を調製する方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
EP0764658B1 (de) * 1995-09-22 2002-01-02 ZLB Bioplasma AG Verfahren zur Gewinnung von Immunglobulinen aus Fraktionen, die bei der Fraktionierung von menschlichem Blutplasma entstehen
WO2002030983A2 (de) 2000-10-13 2002-04-18 Octapharma Ag Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung
AU2004289252C1 (en) 2003-11-08 2013-06-20 Prothera Biologics, Inc. Preparation and composition of Inter-alpha inhibitor proteins from human plasma for therapeutic use
CN101160133B (zh) * 2004-11-05 2013-01-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
WO2008113589A1 (en) * 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
AU2009260822B2 (en) 2008-05-28 2016-09-22 Prothera Biologics, Inc. Preparation and composition of Inter-alpha inhibitor proteins from blood
AT514675B1 (de) * 2009-07-23 2019-05-15 Baxalta Inc Herstellung von faktor h (fh) und fh-derivaten aus plasma
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8841248B2 (en) 2010-07-23 2014-09-23 Baxter International Inc. Manufacture of inter-alpha-inhibitor (IaIp) from plasma

Also Published As

Publication number Publication date
WO2012012773A1 (en) 2012-01-26
EP2596014A1 (en) 2013-05-29
US9505814B2 (en) 2016-11-29
EP2596014B1 (en) 2018-11-28
US20120053113A1 (en) 2012-03-01
US20150045538A1 (en) 2015-02-12
SG187599A1 (en) 2013-03-28
CA2806645A1 (en) 2012-01-26
CN103119058A (zh) 2013-05-22
US8841248B2 (en) 2014-09-23
JP2013535468A (ja) 2013-09-12
EA201390156A1 (ru) 2014-01-30
MX2013000958A (es) 2013-11-20
JP5830096B2 (ja) 2015-12-09
ES2717177T3 (es) 2019-06-19
BR112013001753A2 (pt) 2016-05-31
KR20130093607A (ko) 2013-08-22
AU2011280907A1 (en) 2013-02-07
AU2011280907B2 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
CO6680653A2 (es) Fabricación del inhibidor inter-alfa(iaip) a partir de plasma
PH12014502524B1 (en) Carboxylic acid compounds
AT516600A5 (de) Herstellung von faktor h (fh) und fh-derivaten aus plasma
BRPI0909040A8 (pt) Derivados de azetidina e ciclobutano, seus usos, e composição
AR076800A1 (es) Metodo para producir una preparacion de inmunoglobulina con un alto rendimiento
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
EA201301181A1 (ru) Триазолопиридины
AR081427A1 (es) Metodo para preparar anticuerpos con propiedades mejoradas
PH12013502549B1 (en) Fused benzoxazepinones as ion channel modulators
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
UY32582A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
BR112014018959A8 (pt) Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer
PH12012500620A1 (en) Compounds
CU20130063A7 (es) Proceso de producción de depsipéptidos cíclicos
EA201491028A8 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
UY32673A (es) Nuevas pirimidinas, composiciones farmaceuticas que las contienen, procedimientos de preparaciones y su aplicacion como medicamentos
MX2015003021A (es) Derivados de acido glicirretinico y metodos de uso de los mismos.
AR090425A1 (es) Precipitacion de las fracciones i-iv-1 para obtener inmunoglobulinas plasmaticas
PE20141264A1 (es) Procedimiento de obtencion de una composicion que contiene factores de crecimiento a partir de un compuesto sanguineo, y composicion obtenible por dicho procedimiento
MX2017004131A (es) Metodo y composicion para producir agentes regenerativos anti-inflamatorios/anti-catabolicos mejorados a partir de fluido fisiologico autologo.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
PH12014501342A1 (en) Cosmetic composition containing the slime of snails fed with red ginseng and method for manufacturing same
HK1203772A1 (en) Liquid tobacco compositions
AR086987A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia

Legal Events

Date Code Title Description
FC Application refused